Results 231 to 240 of about 543,220 (340)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Cysteine-enabled cleavability to advance cross-linking mass spectrometry for global analysis of endogenous protein-protein interactions. [PDF]

Nat Commun
Jiao F, Braitbard M, Yu C, Shor B, Wulff BE, Schneidman-Duhovny D, Huang L.   +6 more
europepmc   +1 more source

Mapping the key players in Kawasaki disease; role of inflammatory genes and protein-protein interactions

Wael Hafez, Feras Al‐Obeidat, Asrar Rashid, Afsheen Raza, Nouran Hamza, Nesma Ahmed, Marwa Muhammed Abdeljawad, Raziya Kadwa, Abdelhameed Elmesery, Muneir Gador, Dina Khair, Gihan Zina, Fatema Abdulaal, Mina Wassef Girgiss, M.S. Abd-Elhady, Ahmed S. Abdelrahman, Mahmad Anwar Ibrahim, Mohamed El‐Sherbiny   +17 more
openalex   +1 more source

A near-complete reassembled haplotype-resolved reference genome of Acer truncatum. [PDF]

Sci Data
Wang L, Wang ZW, Ma HY, Sun ZM, Zhang RG, Qin X, Jia KH, Liu D.   +7 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Mapping the BRCA1 Protein Interaction Network: Functional Insights and Therapeutic Implications in Cancer

Oluwatobiloba Kehinde Adedokun, Aliyu O Olaniyi, Happiness Ifedolapo Olaniyi, Basma Alleelwa   +3 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Structural Characterization of Protein-Nucleic Acid Complexes: An Overview of the Recent Innovation in the Analytic Methods. [PDF]

Int J Mol Sci
Bellone ML, Mensitieri F, Marmo E, Calabrese AN, Gaudino G, Izzo V, Dal Piaz F.   +6 more
europepmc   +1 more source